https://assets.capyfin.com/instruments/678fdc13234e27009c5d58a5.png avatar
Stryker
🇺🇸 NYSE:SYK
View Company
OverviewEarningsDividends
•
Dec 31, 2020

Stryker Q4 2020 Earnings Report

Stryker's Q4 2020 results reflected resilience amidst COVID-19 challenges, with net sales increasing by 3.2% and adjusted EPS rising by 12.9%.

Key Takeaways

Stryker reported a 3.2% increase in net sales to $4.3 billion for Q4 2020. Despite challenges from the COVID-19 pandemic, the company's adjusted EPS increased by 12.9% to $2.81. The Wright Medical integration is off to a strong start, and innovation continues across the company.

Net sales increased 3.2% to $4.3 billion.

Organic net sales decreased 1.1%.

Adjusted EPS increased 12.9% to $2.81.

The Wright Medical integration is off to a strong start.

Total Revenue
$4.26B
Previous year: $4.13B
+3.2%
EPS
$2.81
Previous year: $2.49
+12.9%
Organic Net Sales Growth
-1.1%
Previous year: 8%
-113.8%
Gross Profit
$2.72B
Previous year: $2.7B
+0.5%
Cash and Equivalents
$2.94B
Previous year: $4.34B
-32.1%
Free Cash Flow
$1.07B
Previous year: $536M
+100.0%
Total Assets
$34.3B
Previous year: $30.2B
+13.8%

Stryker

Stryker

Stryker Revenue by Segment

Stryker Revenue by Geographic Location

Forward Guidance

Stryker expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019 and adjusted net earnings per diluted share to be in the range of $8.80 to $9.20.

Positive Outlook

  • Expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019
  • Expects adjusted net earnings per diluted share to be in the range of $8.80 to $9.20.
  • Includes the previously announced 10 cents of dilution driven by the acquisition of Wright Medical for the full year.
  • Assumes an ongoing recovery in our key geographies leading to more normalized elective procedure levels during the second quarter of 2021.
  • Expect EPS will be modestly favorable for the full year if foreign currency exchange rates hold near current levels.

Challenges Ahead

  • The impact on our operations and financial results of the COVID-19 pandemic and any related policies and actions by governments or other third parties
  • Unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright
  • Weakening of economic conditions that could adversely affect the level of demand for our products
  • Pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products
  • Potential supply disruptions

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Stryker